Skip to main content

Hohl Benjamin's Form 4 filing

Enliven Therapeutics, Inc. (ELVN) · filed May 7, 2024

Accession no.
0001415889-24-012536
Filed
May 7, 2024
Trade date
May 3, 2024
Filing delay
4 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $22.5K. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Hohl BenjaminCIK 0001882764Officer (CHIEF FINANCIAL OFFICER)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
May 3, 2024Common StockMOption exerciseAcquired+1,000$2.48+$2,4801,000Direct
May 3, 2024Common StockSSaleDisposed−1,000$22.50−$22,5000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
May 3, 2024Common StockMOption exerciseDisposed−1,000$0.00$0221,120Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)